PCSK9 Inhibitors – Does the Benefit Outweigh the Cost?

The results of the GAUSS-3 trial were recently presented at the American College of Cardiology 65th Scientific Session & Expo and were published online in the Journal of the American Medical Association. How did the PCSK9 inhibitor perform among patients with statin intolerance? Was it found to be cost effective? Read more here. (Source: First Report Managed Care, 4/4/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
Leveraging Technology to Reduce Costs in Clinical Trials 06/30/2019
ISMPP, UF College of Pharmacy Announce New Partnership 09/25/2019
ICER Releases Final Report for Type 2 Diabetes Add-on Therapies 12/10/2019
Medical Diagnostics: leveraging new opportunities from AI… 01/16/2020
Accelerated Expansion of MEDiSTRAVA With Acquisition of… 05/21/2019